Altered Abundance of Barrier-Related Proteins in Brain Microvascular Endothelial Cells of the GL261 Mouse Model of Glioblastoma
Molecular Pharmaceutics · 03.11.2025 · 22 (11) · 6658-6669
DOI: 10.1021/acs.molpharmaceut.5c00609 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, online erschienen am 18.10.2025. Verfasst von Liam M Koehn und 10 weiteren Autor:innen. Beteiligte Einrichtung: Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria 3052, Australia. Hauptthemen laut MEDLINE: Blood-Brain Barrier, Endothelial Cells, Glioblastoma, Brain Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 55 Literaturangaben. Gefördert von: Victorian Government for the Centre for Research Excellence in Brain Cancer.
Abstract (Originalsprache)
Glioblastoma multiform (GBM) is a brain cancer that has limited treatment options and a high fatality rate, due in part to limited access of chemotherapeutics to the tumor resulting from the restrictive nature of the blood-brain barrier (BBB). The present study characterized the proteome of endothelial cells forming the BBB in a mouse model of GBM, as a way to identify putative transporters that could be exploited to enhance drug delivery in GBM. Female 6-8 week old C57BL/6 mice were intracranially injected with glioma 261 (GL261) cells or underwent a sham injection. After 28-29 days, brain endothelial cells (CD31+/CD45-) from GL261 (GBM-EC) and sham-injected (control-EC) mice were isolated using magnetic-activated cell sorting, and the proteome of cells was compared by untargeted liquid chromatography dual mass spectrometry. GBM-EC had significantly lower abundance of tight junction proteins (e.g., tight junction protein 1, 0.4-fold) and drug-metabolizing enzymes (e.g., glutathione-S-transferase A4, 0.4-fold) compared to control-EC, alongside an up- and down-regulation of drug transporters (e.g., long-chain fatty acid transport protein 4, 5-fold; adenosine triphosphate binding cassette transporter subfamily B member 1A, 0.3-fold). A large, 7-fold up-regulation of the endothelial cell surface receptor melanoma cell adhesion molecule (MCAM) and scavenger receptor class B member 1 (SCARB1) were identified in GBM-EC compared to control-EC. Immunohistochemistry confirmed cerebral endothelial localization of MCAM and SCARB1 in GBM, in addition to nonvascular patterning within the GBM, suggesting these receptors may be targets that could be exploited for drug delivery. The present study identified changes to BBB markers of paracellular permeability, as well as active and receptor-mediated transcellular transport that could present novel avenues to consider to enhance the permeability and GBM access of current and future therapeutics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria 3052, Australia.
- Cancer Therapies and Biology Group, Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria 3084, Australia.
- Monash Proteomics and Metabolomics Platform, Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria 3168, Australia.
- Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria 3084, Australia.
- School of Cancer Medicine, Latrobe University, Heidelberg, Melbourne 3084, Australia.
- Centre for Drug Candidate Optimisation, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria 3052, Australia.
ORCID-Profile: Liam M Koehn, Joel R Steele, Ralf B Schittenhelm, Joseph A Nicolazzo
Förderung
- Victorian Government for the Centre for Research Excellence in Brain Cancer
Zitieren
APA
Koehn, L. M., Cao, D., Steele, J. R., Rigopoulos, A., Burvenich, I. J., Chung-Lee, H., Tanuwidjaya, E., Schittenhelm, R. B., Scott, A. M., Gan, H. K., & Nicolazzo, J. A. (2025). Altered Abundance of Barrier-Related Proteins in Brain Microvascular Endothelial Cells of the GL261 Mouse Model of Glioblastoma. Molecular Pharmaceutics, 22(11), 6658-6669. https://doi.org/10.1021/acs.molpharmaceut.5c00609
Vancouver
Koehn LM, Cao D, Steele JR, Rigopoulos A, Burvenich IJ, Chung-Lee H, et al. Altered Abundance of Barrier-Related Proteins in Brain Microvascular Endothelial Cells of the GL261 Mouse Model of Glioblastoma. Molecular Pharmaceutics. 2025;22(11):6658-6669. doi:10.1021/acs.molpharmaceut.5c00609
BibTeX
@article{Koehn2025,
author = {Koehn, Liam M and Cao, Diana and Steele, Joel R and Rigopoulos, Angela and Burvenich, Ingrid Jg and Chung-Lee, Han and Tanuwidjaya, Erwin and Schittenhelm, Ralf B and Scott, Andrew M and Gan, Hui K and Nicolazzo, Joseph A},
title = {Altered Abundance of Barrier-Related Proteins in Brain Microvascular Endothelial Cells of the GL261 Mouse Model of Glioblastoma},
journal = {Molecular Pharmaceutics},
year = {2025},
volume = {22},
number = {11},
pages = {6658--6669},
doi = {10.1021/acs.molpharmaceut.5c00609}
}
EUVIMED